Trial · NCT02765841
Registered outcomes28
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 28
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent change in LDL-C | Baseline, Week 24 | |
| Secondary | Percent Change in TC | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 68, 80, 92, 104 | |
| Secondary | Percent change in non-HDL-C | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 68, 80, 92, 104 | |
| Secondary | Percent change in HDL-C | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 68, 80, 92, 104 | |
| Secondary | Percent change in TG | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 68, 80, 92, 104 | |
| Secondary | Percent change in VLDL-C | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 68, 80, 92, 104 | |
| Secondary | Percent change in Lp(a) | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 68, 80, 92, 104 | |
| Secondary | Percent change in apo B | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 68, 80, 92, 104 | |
| Secondary | Percent change in apo A-1 | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 68, 80, 92, 104 | |
| Secondary | Percent change in LDL-C | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 68, 80, 92, 104 | |
| Secondary | Changes in lipid-lowering therapy | Week 24 through Week 104 | |
| Secondary | Changes in LDL apheresis | Week 24 through Week 104 | |
| Secondary | Percent of patients achieving goal (LDL-C of <100 mg/dL [2.6 mmol/L] for patients without documented cardiovascular disease [CVD] at Baseline | Week 24 and through Week 108 | |
| Secondary | Percent of patients achieving goal LDL-C of <70 mg/dL [1.8 mmol/L]) for patients with documented CVD at Baseline. | Week 24 and through Week 108 | |
| Secondary | Changes in laboratory parameters (including hepatic and renal function) | Baseline through Year 2 | |
| Secondary | Reported Adverse Events | Baseline through Year 2 | |
| Secondary | Electrocardiogram (ECG) changes | Baseline through Year 2 | |
| Secondary | Pulmonary function tests (PFTs) | Baseline through Year 2 | |
| Secondary | Bone health/age (x-ray of the wrist) | Baseline through Year 2 | |
| Secondary | Height Measurement | Baseline through Year 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02765841/registered